Introduction {#sec1}
============

Diabetes is a global health burden and its morbidity and mortality are increasing in recent decades, especially in populations from the low- and middle-income countries \[[@B1],[@B2]\]. Diabetes is a systemic metabolic disorder disease that can result in several long-term micro- and macrovascular complications, including diabetic retinopathy (DR) and diabetic nephropathy (DN). It was reported that \~28.5--40.3% of patients with type II diabetes mellitus (T2DM) suffered from DR and 25--40% had DN \[[@B3]\]. To make things worse, DR and DN are serious microvascular complications and have been considered as the major cause of blindness and end-stage renal failure, respectively \[[@B3]\]. Thus, it is very significant for clinicians and researchers to elucidate pathogenesis of DR and DN and identify high-risk patients.

Diabetes mellitus (DM) is a chronic systemic disease. A flood of literatures have suggested that chronic inflammation was involved in insulin resistance and DM development \[[@B6]\]. Moreover, accumulated evidence have implicated that inflammatory response also plays a key part in the development and progression of DR and DN \[[@B10]\]. In the studies exploring the association of chronic inflammation with DR and DN, elevated C-reactive protein levels were observed in patients with DR, as compared in DM patients without DR. Besides, various inflammatory cytokines, such as interleukin-1, -6, -8, and tumor necrosis factor α were also considered to be tightly associated with the pathogenesis of DN. In recent years, neutrophil to lymphocyte ratio (NLR) as a novel indicator of systemic inflammatory response in various diseases emerged and was considered as an independent predictor of major morbidity, mortality, and long-term survival in many clinical settings \[[@B14]\]. Particularly, an increasing evidence showed that NLR was also closely related to the development and progression of DR and DN \[[@B13],[@B17],[@B18]\]. In addition to inflammation, prothrombotic state in DM patients was also reported to be implicated in the development and acceleration. Mean platelet volume (MPV), which can be readily obtained from the hematological analyzers, is a parameter to evaluate the platelet size and can reflect the platelet functions and activation. Platelets with higher MPV value have more metabolic and enzymatic activities than lower size, with more thromboxan-A~2~, b-thromboglobulin, and adhesion molecules releasing \[[@B19],[@B20]\]. Besides, platelet distribution width (PDW) is a parameter that can directly mirror the variability of platelet size. Its high value indicates increased production of larger reticulated platelet and also suggests high activity. Thus, numerous studies have focussed on investigating the relationship of MPV and PDW to the development and progression of DR and DN, and several studies suggested that there was a positive link.

However, in retrospect, the conclusions regarding the relationship of NLR, MPV, and PDW to the development and progression of DR and DN were conflicting \[[@B21]\]. One of the reasons for the inconsistency might be that the sample size was small in a single study and the power of statistical results was challenged. Therefore, we herein performed a meta-analysis and systematic review to comprehensively assess the correlation of NLR, MPV, and PDW with DR and DN.

Methods {#sec2}
=======

This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements \[[@B24]\]. Study selection, data extraction, and quality assessment were completed by two investigators separately.

Study selection {#sec2-1}
---------------

We searched PubMed, Embase, Web of Science, and CNKI up to 11 December 2017 to retrieve eligible studies. Literature search was performed using the following keywords: 'neutrophil to lymphocyte ratio/NLR' or 'mean platelet volume/MPV' or 'platelet distribution/PDW' in combination with 'diabetic retinopathy/DR' or 'diabetic nephropathy/DN'. Moreover, references of the included studies were also examined. No language or date limitations were applied in this meta-analysis.

Inclusion criteria {#sec2-2}
------------------

Studies that met the following inclusion criteria were included in this meta-analysis. (i) The enrolled patients in studies were clearly diagnosed with T2DM. (ii) The data of NLR, MPV, and PDW were presented as the mean value with sufficient data (SD). (iii) There were comparisons of NLR, MPV, and PDW values between DM, and DR or DN.

Exclusion criteria {#sec2-3}
------------------

Studies have been excluded based on the following criteria: (i) reviews, editorials, meeting abstracts, case reports, and non-comparative studies; (ii) duplicate publications; (iii) data were unavailable or only reported in abstracts; (iv) articles were submitted by same authors or institution which might have overlapping patients.

Data extraction {#sec2-4}
---------------

All the data were extracted from each eligible article by two independent reviewers, and all disagreements on eligibility during the extraction were discussed and resolved through a consensus. The extracted information included the name of first author, publication year, study design, country, number of patients in case and control groups, mean age and sex in each group, the mean value with SD of NLR, MPV, PDW.

Methodology quality assessment {#sec2-5}
------------------------------

The Newcastle--Ottawa scale (NOS) was used for the assessment of included studies \[[@B25]\]. And a score of 0--9 points has been assigned to each study, and studies ≥6 points were considered to be of relatively high quality.

Statistical analysis {#sec2-6}
--------------------

The statistical analysis was performed by using STATA version 12.0 (Stata Corporation, College Station, TX, U.S.A.). Standard mean difference (SMD) and its 95% confidence interval (CI) was used to depict the pooled continuous variables. If the data of NLR, MPV, and PDW were reported in non-proliferative DR/proliferative DR (NPDR/PDR) or microalbuminuria/macroalbuminuria (MIA/MA) groups, the data in NPDR or MIA were used to compare with control group. Based on the 95% CI not crossing 0, the SMD \< 0 suggested that the specific hematologic inflammatory marker increased in control group. In addition, statistical heterogeneity amongst the studies was evaluated by Cochrane *Q* test (χ^2^) and *I^2^* test. Moreover, a random-effect model was conducted to calculate the SMD when significant heterogeneity existed amongst some studies (*P*\<0.05 and *I^2^* ≥ 50%), otherwise, fixed-effect model was used. Sensitivity analysis was performed to verify the stabilization of our results, by excluding the articles one by one in each corresponding group, and then obtained meta-analysis results from the remaining studies. Furthermore, the Begg's test and Egger's test were performed to evaluate the publication bias \[[@B26],[@B27]\]. If the significant publications bias exist (*P*\<0.01 for Begg's test and Egger's test), Duval wnd Tweedie's \[[@B28]\] non-parametric trim-and-fill method was conducted to evaluate the effects of bias on the results.

Results {#sec3}
=======

Study selection {#sec3-1}
---------------

The flow chart diagram of the process of study selection was shown in [Figure 1](#F1){ref-type="fig"}. A total of 190 articles were yielded through primary study searching for PubMed, Embase, Web of Science, and CNKI. Of these studies, 44 were from PubMed, 67 from Embase, 52 from Web of Science, and 27 from CNKI. Amongst these studies, 17 articles were removed because of duplication, and 105 publications were excluded due to reviews, meeting abstracts, and studies not pertinent to DR or DN after screening the title and abstract. Thus, the remaining 68 articles were left for the full-text review. Of the 68 studies, 9 articles were excluded since control group's subjects were not DM patients, but healthy people, and 11 articles were removed owing to the lack of available data. Finally, 48 articles with 9118 patients were enrolled in this meta-analysis \[[@B21],[@B29]\].

![Flow chart of study selection process](bsr-38-bsr20180172-g1){#F1}

Characteristics of included studies {#sec3-2}
-----------------------------------

All the selected studies were published from 2000 to 2017. The number of the included subjects in the case group and the control group ranged from 20 to 328 and 20 to 192, respectively. Of these 48 articles, 27 came from China \[[@B22],[@B30],[@B34],[@B36],[@B37],[@B41],[@B43],[@B48],[@B49],[@B55],[@B64],[@B65],[@B67],[@B68],[@B70]\], 16 from Turkey \[[@B21],[@B23],[@B29],[@B31],[@B35],[@B38],[@B40],[@B42],[@B47],[@B50],[@B61],[@B69]\], 3 from India \[[@B32],[@B63],[@B39]\], 1 from Greece \[[@B62]\] and 1 from Kazakhstan \[[@B33]\]. Amongst these studies, 21 reported NLR (9 enrolled patients with DR, 12 enrolled patients with DN) \[[@B21],[@B23],[@B31],[@B32],[@B34],[@B35],[@B38],[@B41],[@B45],[@B47],[@B50],[@B56],[@B62],[@B63],[@B65],[@B67],[@B71]\], 33 reported the data of MPV (23 enrolled patients with DR, 10 enrolled patients with DN) \[[@B22],[@B29],[@B30],[@B33],[@B36],[@B44],[@B46],[@B48],[@B55],[@B61],[@B64],[@B66],[@B70],[@B73]\], and 12 reported PDW (12 enrolled patients with DR, 3 enrolled patients with DN) \[[@B21],[@B23],[@B32],[@B41],[@B43],[@B50],[@B58],[@B65],[@B67],[@B71]\]. The basic characteristics and data of our interest of the eligible studies were summarized in [Tables 1--6](#T1){ref-type="table"}. Moreover, the methodological quality of the included articles were assessed according to NOS, and the scores ranged from 5 to 7, indicating that the quality of selected studies were moderate to high.

###### The main characteristics of the included studies on the relationship of MPV and PDW with diabetic nephropathy

  -------------------------------------------------------------------------------------------------------------------------------
                                           No. of patients                                                                    
  --------------------------- --- -------- ----------------- ----- ---------------------- -------------------- -------------- ---
  Bavbek 2007 \[[@B31]\]      R   Turkey   39                75    P(-): 59.5 ± 8.1\      P(-): 27/12\         6              
                                                                   P(+): 59.4 ± 10.8      P(+): 47/28                         

  Buch 2017 \[[@B32]\]        R   India    264               36    NR                     NR                   7              

  Dindar 2013 \[[@B35]\]      R   Turkey   35                25    NR                     NR                   6              

  Kahraman 2016 \[[@B39]\]    R   Turkey   54                34    24                     P(-): 59.9 ±7.9\     P(-): 16/38\   7
                                                                                          MIA: 64.1 ±8.9\      MIA: 16/18\    
                                                                                          MA: 56.8 ±12.5       MA: 7/17       

  UNUBOL 2011 \[[@B42]\]      R   Turkey   230               124   P(-): 56.87±9.65\      P(-): 108/122\       7              
                                                                   P(+): 55.73±11.07      P(+): 54/70                         

  Turgutalp 2012 \[[@B47]\]   R   Turkey   160               144   P(-): 55.14 + 10.90\   P(-): 77/83\         7              
                                                                   P(+): 54.08 + 12.16    P(+): 74/70                         

  Cui 2006 \[[@B34]\]         R   China    30                42    NR                     P(-): 15/15\         6              
                                                                                          P(+): 20/22                         

  Liang 2008 \[[@B41]\]       R   China    68                68    P(-): 69.1\            P(-): 32/36\         6              
                                                                   P(+): 67.1             P(+): 30/38                         

  Ma 2007 \[[@B43]\]          R   China    72                80    P(-): 67.6\            P(-): 32/40\         6              
                                                                   P(+): 68.3             P(+): 34/46                         

  Sun 2007 \[[@B45]\]         R   China    35                31    30                     P(-): 57.3±14.6\     P(-): 18/17\   6
                                                                                          MIA: 57.6±13.5\      MIA: 16/15\    
                                                                                          MA: 58.2±13.2        MA: 16/14      

  Akbas 2014 \[[@B29]\]       R   Turkey   132               34    34                     P(-): 56.03±10.54\   P(-): 69/63\   7
                                                                                          MIA: 60.35±11.40\    MIA: 16/18\    
                                                                                          MA: 59.03±9.61       MA: 18/16      

  Ao 2017 \[[@B30]\]          R   China    80                100   100                    P(-): 57.1±11.1\     P(-): 41/39\   7
                                                                                          MIA: 56.4±8.5\       MIA: 55/45\    
                                                                                          MA: 70.6±7.6         MA: 56/44      

  Ciray 2015 \[[@B33]\]       R   USA      52                62    P(-): 56.9 ± 10.1\     NR                   6              
                                                                   P(+): 62.1 ± 11.7                                          

  Demirtas 2015 \[[@B53]\]    R   Turkey   193               114   NR                     NR                   6              

  Huang 2014 \[[@B37]\]       R   China    138               115   NR                     NR                   6              

  Feng 2016 \[[@B36]\]        R   China    38                52    30                     P(-): 61.8±9.1\      P(-): 23/15\   6
                                                                                          MIA: 57.7±10.80\     MIA: 18/34\    
                                                                                          MA: 63.1±10.1        MA: 16/14      

  Kahraman 2016 \[[@B38]\]    R   Turkey   54                34    24                     P(-): 59.9 ±7.9\     P(-): 16/38\   7
                                                                                          MIA: 64.1 ±8.9\      MIA: 16/18\    
                                                                                          MA: 56.8 ±12.5       MA: 7/17       

  Khandare 2017 \[[@B39]\]    R   India    56                59    P(-): 50.05±11.29\     P(-): 26/33\         5              
                                                                   P(+): 52.29±11.45      P(+): 25/31                         

  Ren 2015 \[[@B44]\]         R   China    165               124   41                     P(-): 56.90±11.25\   P(-): 81/84\   6
                                                                                          MIA: 55.35±11.26\    MIA: 71/53\    
                                                                                          MA: 55.02±10.04      MA: 26/15      

  Tian 2017 \[[@B46]\]        R   China    72                49    P(-): 57.32±10.43\     P(-): 39/33\         5              
                                                                   P(+): 61.14±12.03      P(+): 29/20                         

  Xu 2016 \[[@B48]\]          R   China    86                74    P(-): 44.41±10.81\     P(-): 48/38\         6              
                                                                   P(+): 49.22±12.71      P(+): 48/26                         

  Zhu 2016 \[[@B49]\]         R   China    180               112   P(-): 45.270±7.542\    P(-): 80/100\        7              
                                                                   P(+): 48.070±9.377     P(+): 60/52                         
  -------------------------------------------------------------------------------------------------------------------------------

Abbreviation: R: Retrospective study design; P: Proteinuria; MIA: Microalbuminuria; MA: Macroalbuminuria

###### values of NLR in T2DM subjects with and without diabetic nephropathy

                             Neutrophil to Lymphocyte Ratio                                       
  -------------------------- -------------------------------- ------- ------------- ------ ------ ------
  Akbas 2014 \[[@B29]\]      1.56                             0.85    1.96          0.73   2.03   1.52
  Ao 2017 \[[@B30]\]         1.67                             0.54    1.85          0.77   2.44   0.73
  Ciray 2015 \[[@B33]\]      1.77                             0.56    2.27 ± 1.25                 
  Demirtas 2015 \[[@B53]\]   1.68                             0.20    1.99±0.28                   
  Huang 2014 \[[@B37]\]      2.20                             0.62    2.48±0.59                   
  Feng 2016 \[[@B36]\]       2.03                             1.26    2.72          1.47   3.54   1.15
  Kahraman 2016 \[[@B38]\]   1.9                              0.9     2.6           1.0    3.6    1.3
  Khandare 2017 \[[@B39]\]   1.94                             0.65    2.83±0.85                   
  Ren 2015 \[[@B44]\]        1.84                             0.61    2.14          1.30   2.74   1.74
  Tian 2017 \[[@B46]\]       1.76                             0.76    2.14±1.06                   
  Xu 2016 \[[@B48]\]         1.81                             0.56    2.27±0.92                   
  Zhu 2016 \[[@B49]\]        1.836                            0.733   2.654±1.465                 

###### The values of mean platelet volume and platelet distribution width T2DM subjects with and without diabetic nephropathy

                              Mean Platelet Volume (fl)   Platelet Distribution Width (%)                                                        
  --------------------------- --------------------------- --------------------------------- ------------- ------- ------- ------------ ---- ---- ----
  Bavbek 2007 \[[@B31]\]      8.3                         1.3                               8.6±1.3       NR      NR      NR           NR   NR   
  Buch 2017 \[[@B32]\]        10.47                       2.06                              11.01±2.23    13.99   3.48    15.72±3.97             
  Dindar 2013 \[[@B35]\]      10.80                       1.09                              11.07±1.13    NR      NR      NR                     
  Kahraman 2016 \[[@B38]\]    8.8                         1.0                               8.8           1.2     8.3     0.9          NR   NR   NR
  UNUBOL 2011 \[[@B42]\]      8.61                        1.06                              8.95±1.14     NR      NR      NR                     
  Turgutalp 2012 \[[@B47]\]   9.85                        0.74                              10.61± 0.55   NR      NR      NR                     
  Cui 2006 \[[@B34]\]         8.3                         1.1                               9.1±1.3       NR      NR      NR                     
  Liang 2008 \[[@B41]\]       10.2                        1.2                               13.2±1.3      17.1    1.2     18.2±1.2               
  Ma 2007 \[[@B43]\]          8.3                         1.1                               10.3±1.3      17.2    1.3     18.1±1.3               
  Sun 2007 \[[@B45]\]         8.25                        1.13                              10.13         2.01    11.19   2.56         NR   NR   NR

Abbreviation: MIA: Microalbuminuria; MA: Macroalbuminuria

###### The main characteristics of the included studies on the relationship of MPV and PDW diabetic retinopathy

  -----------------------------------------------------------------------------------------------------------------------------------
                                                           No. of                                                                 
  --------------------------- --------------- ------------ -------- ----- ------------------ --------------------- -------------- ---
  Akdoğan 2016 \[[@B50]\]     Retrospective   Turkey       158      120   DM:57.3±12.2\      DM: 59/99\            7              
                                                                          DR: 59.8±9.2\      DR: 47/73                            

  Ateş 2009 \[[@B51]\]        Retrospective   Turkey       30       30    30                 NR                    NR             5

  Buch, 2017 \[[@B32]\]       Retrospective   India        220      80    NR                 NR                    6              

  Citirik 2015 \[[@B23]\]     Prospective     Turkey       43       45    52                 DM:60.4 ± 8.5\        DM: 22/21\     6
                                                                                             NPDR:61.4 ± 9.3\      NPDR: 17/28\   
                                                                                             PDR:59.4 ± 7.2        PDR: 20/32     

  Demirtas 2015 \[[@B53]\]    Prospective     Turkey       240      67    NR                 NR                    7              

  Dindar 2013 \[[@B35]\]      Retrospective   Turkey       36       24    NR                 NR                    6              

  GÜNGÖR 2016 \[[@B54]\]      Retrospective   Turkey       50       52    NR                 DM: 19/31\            6              
                                                                                             DR: 18/34                            

  Li 2014 \[[@B56]\]          Retrospective   China        72       67    70                 DM:54.2 ± 9.2\        DM:35/37\      7
                                                                                             NPDR:57.7± 10.0\      NPDR:34/33\    
                                                                                             PDR:58.3 ± 9.4        PDR:33/37      

  Li 2013 \[[@B57]\]          Retrospective   China        103      132   NR                 NR                    7              

  Li 2016 \[[@B58]\]          Retrospective   China        52       47    DM: 55.1±15.2\     DM: 31/21\            6              
                                                                          DR: 54.1±10.8      DR:26/21                             

  Ma 2017 \[[@B59]\]          Retrospective   China        20       20    20                 DM:57.3± 6.5\         DM:12/8\       5
                                                                                             NPDR:60.8± 7.3\       NPDR:8/12\     
                                                                                             PDR:57.6 ± 7.3        PDR:12/8       

  Niu 2013 \[[@B60]\]         Retrospective   China        20       25    DM:46.5±8.3\       DM:12/8\              6              
                                                                          DR:51.2±8.3        DR:13/12                             

  Papanas 2004 \[[@B62]\]     Retrospective   Greece       89       167   NR                 NR                    7              

  Radha 2016 \[[@B63]\]       Retrospective   India        30       14    NR                 NR                    5              

  Sheng 2017 \[[@B64]\]       Retrospective   China        102      102   NR                 NR                    7              

  Tetikoğlu 2016 \[[@B21]\]   Retrospective   Turkey       63       56    80                 NR                    NR             6

  Tuzcu 2014 \[[@B52]\]       Retrospective   Turkey       70       64    58                 DM: 55.8 ±10.5\       DM:38/32\      6
                                                                                             NPDR: 60.1 ± 8.6\     NPDR:32/32\    
                                                                                             PDR: 57.5 ± 9.3       PDR:31/27      

  Wei 2017 \[[@B67]\]         Retrospective   China        94       52    40                 DM: 58.14 ± 11.93\    DM:50/44\      7
                                                                                             DR: 58.42 ± 12.09     DR:49/43       

  Xu 2014 \[[@B68]\]          Retrospective   China        45       40    NR                 DM: 23/22\            6              
                                                                                             DR:26/14                             

  Yilmaz 2016 \[[@B69]\]      prospective     Turkey       89       88    86                 DM: 60.9 ± 6.3\       DM:49/40\      7
                                                                                             NPDR: 62.7 ± 7.2\     NPDR:48/40\    
                                                                                             PDR: 61.7 ± 7.9       PDR:49/37      

  Yu 2000 \[[@B71]\]          Retrospective   China        60       40    NR                 NR                    6              

  Yue 2015 \[[@B22]\]         Retrospective   China        125      62    59                 DM: 56.00 ± 3.75\     DM:73/52\      6
                                                                                             NPDR: 53.50 ± 3.56\   NPDR:34/28\    
                                                                                             PDR: 56.0 ± 3         PDR:28/31      

  Zhang 2002 \[[@B72]\]       Retrospective   China        20       20    DM:58.0±9.0\       DM: 9/11\             5              
                                                                          DR:60.0±1.3        DR:8/12                              

  Zhou 2016 \[[@B73]\]        Retrospective   China        328      51    DM: 57 ±16\        DM: 198/130\          6              
                                                                          DR: 63 ±15         DR: 34/17                            

  Akdoğan 2016 \[[@B50]\]     Retrospective   Turkey       158      120   DM:57.3±12.2\      DM: 59/99\            7              
                                                                          DR: 59.8±9.2       DR: 47/73                            

  Ciray 2015 \[[@B33]\]       Retrospective   Kazakhstan   59       55    DM: 57.8 ± 11.5\   NR                    6              
                                                                          DR: 61.8 ± 10.8                                         

  Kuang 2015 \[[@B55]\]       Retrospective   China        62       44    22                 DM:60.73 ± 11.24\     DM:29/33\      6
                                                                                             NPDR:60.50 ± 8.45\    NPDR:17/27\    
                                                                                             PDR:55.18 ± 13.05     PDR:11/11      

  Öztürk 2013 \[[@B61]\]      Retrospective   Turkey       97       79    NR                 NR                    NR             6

  Shen 2016 \[[@B64]\]        Retrospective   China        118      134   58                 DM:55.19 ± 5.51\      DM:63/55\      6
                                                                                             NPDR:58.04 ± 7.53\    NPDR:73/61\    
                                                                                             PDR:59.84 ± 8.76      PDR:34/24      

  Ulu 2013 \[[@B66]\]         Retrospective   Turkey       34       24    NR                 NR                    6              

  Wei 2017 \[[@B67]\]         Retrospective   China        94       52    40                 DM: 58.14 ± 11.93\    DM:50/44\      6
                                                                                             DR: 58.42 ± 12.09     DR:49/43       

  Wang 2015 \[[@B18]\]        Retrospective   China        138      131   DM: 60.3 ± 6.0\    DM:65/73\             6              
                                                                          DR: 66.6 ± 5.8     DR:53/78                             

  Yin 2015 \[[@B70]\]         Retrospective   China        64       28    36                 DM: 56.83 ± 9.01\     DM:35/29\      6
                                                                                             NPDR: 53.09 ± 8.82\   NPDR:13/15\    
                                                                                             PDR: 53.16 ± 10.64    PDR:19/17      

  Yue 2015 \[[@B22]\]         Retrospective   China        125      62    59                 DM: 56.00 ± 3.75\     DM:73/52\      6
                                                                                             NPDR: 53.50 ± 3.56\   NPDR:34/28\    
                                                                                             PDR: 56.0 ± 3         PDR:28/31      

  Zhou 2016 \[[@B73]\]        Retrospective   China        328      51    DM: 57 ±16\        DM: 198/130\          6              
                                                                          DR: 63 ±15         DR: 34/17                            
  -----------------------------------------------------------------------------------------------------------------------------------

Abbreviation: DM: Diabetes mellitus; NPDR: Non-proliferative diabetic retinopathy; PDR: Proliferative diabetic retinopathy.

###### values of NLR in T2DM subjects with and without diabetic retinopathy

                           Neutrophil to Lymphocyte Ratio (%)   Platelet to Lymphocyte Ratio (%)                                                                                             
  ------------------------ ------------------------------------ ---------------------------------- ------------- ------ ------ ---------- ------- -------- ---------------- ------- -------- -------
  Akdoğan \[[@B50]\]       2.4                                  1.9                                3.0 ± 4.4     116    66     140 ± 87                                                      
  Ciray 2015 \[[@B33]\]    1.99                                 1.03                               2.10 ± 1.02   NR     NR     NR         NR                                                 
  Kuang 2015 \[[@B55]\]    1.68                                 0.48                               2.20          0.40   2.58   0.41       NR      NR       NR               NR               
  Öztürk 2013 \[[@B61]\]   2.04                                 0.72                               2.58±1.34     NR     NR     NR         NR                                                 
  Shen 2016 \[[@B64]\]     1.52                                 0.26                               1.68          0.21   1.95   0.17       NR      NR       NR               NR               
  Ulu 2013 \[[@B66]\]      1.96                                 0.86                               3.59 ±2.07    NR     NR     NR         NR                                                 
  Wei 2017 \[[@B67]\]      NR                                   NR                                 NR            NR     NR                98.46   10.63    127.25 ± 12.98                    
  Wang 2015 \[\]           2.1                                  1.3                                3.7 ± 1.4     NR     NR     NR         NR                                                 
  Yin 2015 \[[@B70]\]      1.54                                 0.55                               1.83          0.59   2.15   0.77       NR      NR       NR               NR               
  Yue 2015 \[[@B22]\]      1.74                                 0.245                              2.05          0.3    1.91   0.28       94.04   12.365   105.07           17.47   115.73   14.54
  Zhou 2016 \[[@B73]\]     2.4                                  1.5                                4.4±2.7       NR     NR     NR         NR                                                 

Abbreviation: NLR: Neutrophil to lymphocyte ratio; T2DM: Type 2 diabetes mellitus; NPDR: Non-proliferative diabetic retinopathy; PDR: Proliferative diabetic retinopathy.

###### values of MPV and PDW in T2DM subjects with and without diabetic retinopathy

                              Mean Platelet Volume (fl)   Platelet Distribution Width (%)                                                                                       
  --------------------------- --------------------------- --------------------------------- -------------- ------- ------- -------------- ------- ------ ------- ------ ------- ------
  Akdoğan 2016 \[[@B50]\]     9.7                         1.2                               9.6 ± 1.0      16.2    0.8     16.2 ± 0.5                                           
  Ateş 2009 \[[@B51]\]        7.76                        0.72                              7.94           0.61    8.18    0.89           NR      NR     NR      NR     NR      NR
  Buch, 2017 \[[@B32]\]       10.24                       2.04                              11.40 ± 1.96   13.94   3.33    14.92 ± 4.14                                         
  Citirik 2015 \[[@B23]\]     7.94                        0.63                              8.05           0.76    8.10    0.68           14.85   1.27   15.15   1.19   14.92   1.15
  Demirtas 2015 \[[@B53]\]    9.20                        0.92                              9.54±0.88      NR      NR      NR             NR      NR     NR                     
  Dindar 2013 \[[@B35]\]      10.68                       1.68                              11.26 ± 1.08   NR      NR      NR             NR      NR     NR                     
  GÜNGÖR 2016 \[[@B54]\]      8.8                         1.1                               9.3 ± 1.0      NR      NR      NR             NR      NR     NR                     
  Li 2014 \[[@B56]\]          7.8                         1.1                               8.3            1.38    8.9     1.65           NR      NR     NR      NR     NR      NR
  Li 2013 \[[@B57]\]          9.05                        0.44                              9.73 ± 0.53    NR      NR      NR             NR      NR     NR                     
  Li 2016 \[[@B58]\]          10.39                       0.90                              10.72 ± 1.57   13.80   3.32    16.17 ± 1.66                                         
  Ma 2017 \[[@B59]\]          8.12                        0.82                              8.96           0.86    10.76   1.12           15.66   2.37   17.85   2.26   17.90   2.41
  Niu 2013 \[[@B60]\]         10.25                       2.04                              14.21 ± 2.35   16.05   1.56    18.12 ± 1.25                                         
  Papanas 2004 \[[@B62]\]     10.9                        1.1                               15.8 ± 1.3     NR      NR      NR             NR      NR     NR                     
  Radha 2016 \[[@B63]\]       8.39                        0.67                              9.2 ± 0.61     NR      NR      NR             NR      NR     NR                     
  Sheng 2017 \[[@B65]\]       9.76                        0.86                              10.17 ± 0.92   11.31   1.67    12.04 ± 1.88                                         
  Tetikoğlu 2016 \[[@B21]\]   8.51                        1.0                               8.42           0.9     8.91    0.7            16.9    0.7    16.8    0.7    17.3    3.1
  Tuzcu 2014 \[[@B52]\]       7.90                        1.26                              8.20           1.55    8.78    1.73           NR      NR     NR      NR     NR      NR
  Wei 2017 \[[@B67]\]         11.12                       1.3                               11.50          1.39    11.56   1.06           13.70   2.90   14.40   2.88   14.20   1.99
  Xu 2012 \[[@B68]\]          11.21                       1.71                              13.44 ± 2.01   15.98   1.23    17.41 ± 1.42                                         
  Yilmaz 2016 \[[@B69]\]      7.84                        0.76                              7.90           0.85    8.31    0.76           13.02   1.29   13.49   1.18   13.77   1.26
  Yu 2000 \[[@B71]\]          10.93                       2.35                              13.08 ± 2.04   17.77   1.97    21.48 ± 5.94                                         
  Yue 2015 \[[@B22]\]         NR                          NR                                NR             NR      NR      NR                                                   
  Zhang 2002 \[[@B72]\]       9.82                        1.53                              10.19 ± 2.06   NR      NR      NR             NR      NR     NR                     
  Zhou 2016 \[[@B73]\]        10.0                        1.1                               10.4 ± 1.1     NR      NR      NR             NR      NR     NR                     

Abbreviation: T2DM: Type 2 diabetes mellitus; NPDR: Non-proliferative diabetic retinopathy; PDR: Proliferative diabetic retinopathy.

Meta-analysis results {#sec3-3}
---------------------

### The association of NLR with DN and degree of albuminuria {#sec3-3-1}

A total of 12 studies involving 2404 patients were included for the meta-analysis of the association of NLR with the presence of DN \[[@B29],[@B30],[@B33],[@B36],[@B44],[@B46],[@B48],[@B49]\], and 5 articles reported the data regarding the relationship between NLR and degree of albuminuria (MIA and MA) \[[@B29],[@B30],[@B36],[@B38],[@B44]\]. Random-effect model was applied since the significant heterogeneity was present for the presence of DN (*I^2^* = 80.0; *P*\<0.01), and degree of albuminuria (*I^2^* = 53.1; *P*=0.07). From the results of our meta-analysis, NLR level was significantly higher in patients with DN (SMD = 0.63; 95% CI: 0.43--0.83) ([Figure 2](#F2){ref-type="fig"}A) and MA (SMD = 0.56; 95% CI: 0.29--0.82) ([Figure 2](#F2){ref-type="fig"}B), as compared with those without DN and MIA.

![Results of forest plot of the relationship between NLR and DN\
Forest plot of the relationship between NLR and DN (**A**); forest plot of the relationship between NLR and the degree of DN (**B**).](bsr-38-bsr20180172-g2){#F2}

### The association of NLR with DR {#sec3-3-2}

A total of ten studies with 1911 patients, which provided the data about the association of NLR with the presence of DR \[[@B22],[@B33],[@B50],[@B55],[@B61],[@B64],[@B66],[@B70],[@B73]\], were included in this meta-analysis. The heterogeneity tests showed the extinction of significant heterogeneity (*I^2^* = 86.5; *P*\<0.01), so random-effect model was used. The results suggested that NLR level was substantially higher in patients with DR (SMD = 0.77; 95% CI: 0.49--1.05) ([Figure 3](#F3){ref-type="fig"}A) than those without DR. Additionally, four articles with 443 patients were also included for the meta-analysis of the association between NLR and the degree of DR (NPDR and PDR). However, no significant association between NLR and the degree of DR was observed in this meta-analysis (SMD = 0.57; 95% CI: −0.34--1.47) ([Figure 3](#F3){ref-type="fig"}B).

![Results of forest plot of the relationship between NLR and DR\
Forest plot of the relationship between NLR and DR (**A**); forest plot of the relationship between NLR and the degree of DR (**B**).](bsr-38-bsr20180172-g3){#F3}

### The association of MPV with DN {#sec3-3-3}

A total of ten studies with 1700 patients reported the data of MPV for DN \[[@B31],[@B32],[@B34],[@B35],[@B38],[@B41],[@B45],[@B47]\]. Considering the significant heterogeneity (*I^2^* = 93.3; *P*\<0.01), random-effect meta-analysis was conducted and the results showed that MPV was higher in patients with DN than DM patients without DN (SMD = 0.81; 95% CI: 0.36--1.25) ([Figure 4](#F4){ref-type="fig"}).

![Forest plot of the relationship between MPV and DN](bsr-38-bsr20180172-g4){#F4}

### The association of MPV with DR {#sec3-3-4}

There were 23 articles with 3437 patients, which had data of MPV for DR \[[@B21],[@B23],[@B32],[@B35],[@B50],[@B56],[@B62],[@B63],[@B65],[@B67],[@B71]\]. Random-effects model was used to pool the data because of the significant heterogeneity amongst the included studies (*I^*2*^* = 94.1; *P*\<0.01). From the result, we observed that MPV was higher in DR group as compared with DM patients without DR (SMD = 0.68; 95% CI: 0.36--0.99) ([Figure 5](#F5){ref-type="fig"}A). Moreover, a total of eight studies with 858 patients investigated the association of MPV with the degree of DR. Similarly, random-effect model was applied due to the significant heterogeneity (*I^2^* = 67.3; *P*\<0.01). The result showed that MPV level was significantly higher in patients with PDR than in NPDR (SMD = 0.44; 95% CI: 0.20--0.69), indicating that MPV was closely correlated with the progression of DR ([Figure 5](#F5){ref-type="fig"}B).

![Results of forest plot of the relationship between MPV and DR\
Forest plot of the relationship between MPV and DR (**A**); forest plot of the relationship between MPV and the degree of DR (**B**).](bsr-38-bsr20180172-g5){#F5}

### The association of PDW with DN {#sec3-3-5}

Three articles with 588 patients were included in the meta-analysis of the association between PDW and DN \[[@B32],[@B41],[@B43]\]. Heterogeneity analysis indicated the absence of significant heterogeneity (*I^2^* = 29.6; *P*=0.241), so fixed-effect model was used. The result of meta-analysis showed that PDW level was elevated in DR group compared with DM group (SMD = 0.70; 95% CI: 0.50--0.90) ([Figure 6](#F6){ref-type="fig"}).

![Forest plot of the relationship between PDW and DN](bsr-38-bsr20180172-g6){#F6}

### The association of PDW with DR {#sec3-3-6}

A total of 12 articles with 1681 patients explored the relationship between PDW and DR \[[@B21],[@B23],[@B32],[@B50],[@B58],[@B65],[@B67],[@B71]\]. Considering the significant heterogeneity amongst the 12 studies (*I^2^* = 79.3; *P*\<0.01), random-effect model was applied when we performed the meta-analysis. As the results showed, PDW level was significantly higher in DR group (SMD = 0.52; 95% CI: 0.28--0.76) than in DM group ([Figure 7](#F7){ref-type="fig"}A). Furthermore, there were five studies with 539 patients, which referred to the relationship between PDW and the severity of DR. Hence, in the present study, we also performed the meta-analysis to investigate relationship between PDW and the severity of DR. However, the result indicated that there was no significant association of PDW with the severity of DR (SMD = 0.08; 95% CI: --0.09--0.25) ([Figure 7](#F7){ref-type="fig"}B).

![Results of forest plot of the relationship between PDW and DR\
Forest plot of the relationship between PDW and DR (**A**); forest plot of the relationship between PDW and the degree of DR (**B**).](bsr-38-bsr20180172-g7){#F7}

Sensitive analysis {#sec3-4}
------------------

For the purpose of verifying the robustness of the meta-analysis results, we conducted sensitivity analysis by excluding the articles one by one in each step, and then obtained the meta-analysis results of the remaining studies. The results implied that the synthesized SMDs of NLR for DN ([Figure 8](#F8){ref-type="fig"}A), NLR for DR ([Figure 8](#F8){ref-type="fig"}B), as well as MPV for DN ([Figure 8](#F8){ref-type="fig"}C), MPV for DR ([Figure 8](#F8){ref-type="fig"}D) and PDW for DR ([Figure 8](#F8){ref-type="fig"}E) did not change substantially when omitting any individual study, indicating that the results of meta-analysis were robust although significant heterogeneity existed amongst the included studies. Owing to the limitation of study number, sensitivity analysis was not applicable for the synthesized SMDs of the other data.

![The sensitive analysis of selected studies\
NLR for DN (**A**), NLR for DR (**B**), MPV for DN (**C**), MPV for DR (**D**), PDW for DR (**E**).](bsr-38-bsr20180172-g8){#F8}

Publication bias {#sec3-5}
----------------

The assessment of publication bias of the included studies was performed by using Begg's and Egger's test. From the results of the publication bias test, we found that there was no evidence of publication bias for the pooled SMDs of NLR for DN (Begg's test, *P*=0.244; Egger's test, *P*=0.990) ([Figure 9](#F9){ref-type="fig"}A) and for DR (Begg's test, *P*=0.929; Egger's test, *P*=0.588) ([Figure 9](#F9){ref-type="fig"}B). Similarly, the publication bias for the pooled SMD of MPV for DN was not observed either (Begg's test, *P*=0.371; Egger's test, *P*=0.690) ([Figure 9](#F9){ref-type="fig"}C).

![The funnel plots for the assessment of potential publication bias\
NLR for DN (**A**), NLR for DR (**B**), MPV for DR (**C**), MPV for DR (**D**), PDW for DR (**E**).](bsr-38-bsr20180172-g9){#F9}

Nevertheless, publication bias might exist amongst the eligible studies referring to MPV (Begg's test, *P*=0.039; Egger's test, *P*=0.148) ([Figure 9](#F9){ref-type="fig"}D) and PDW (Begg's tests, *P*=0.06; Egger's tests, *P*=0.02) ([Figure 9](#F9){ref-type="fig"}E) for DR. Consequently, we used meta-trim method to figure out the effect of publication bias on the dependability of the meta-analysis results. The results of meta-trim method showed that the adjusted SMDs of MPV and PDW were (0.68; 95% CI: 0.36--0.99) and (0.28; 95% CI: 0.018--0.540), respectively, indicating that the publication bias did not substantially affect the stability of the pooled results of the MPV and PDW for DR. In addition, the publication bias test was not applicable for the pooled SMD of PDW for DN owing to the limitation of the number of the eligible studies.

Discussion {#sec4}
==========

To our knowledge, this is the first meta-analysis focussing on the association of NLR, MPV, and PDW with DN and DR. In our meta-analysis, we found that NLR, MPV, and PDW was higher in patients with DR or DN. In addition, we also observed that MPV was strongly associated with the severity of DR, and NLR was closely related to the degree of DN.

White blood cells and their subtypes have been widely considered as inflammatory markers in various diseases including DM. NLR calculated by blood routine examination is readily available and inexpensive. It has better stability since it reflects the balance between the peripheral blood neutrophils and lymphocytes, which is less affected by various physiological and pathological status, as compared with independent neutrophils, lymphocytes, and total white blood cell count. In recent years, studies have reported that NLR might be a novel inflammatory marker, and there was a significant relationship of NLR to conventional markers of inflammation. For instance, several studies showed that there was a positive association of NLR with serum IL-6 and C-reactive protein \[[@B74],[@B75]\]. Furthermore, it has been recognized that chronic inflammation has a significant role in the development and deterioration of DM-associated complications \[[@B76]\]. Several studies have reported that various inflammatory molecules such as adipokines, chemokines, adhesion molecules, and cytokines, could contribute to the development of DN \[[@B77]\]. A study showed that NLR, as a novel inflammation marker, is inversely associated with glomerular filtration rate (GFR) patients with chronic kidney disease \[[@B14]\]. Particularly, a 3-year follow-up study showed that NLR could serve as a predictor of worsening renal function in diabetes patients \[[@B78]\]. Additionally, numerous studies have shown that elevated NLR was associated with the presence of DN and MA \[[@B75],[@B79]\]. In consistence with that, this meta-analysis confirmed that DM patients with DN, albuminuria, or MA have higher NLR, as compared with those without DN, albuminuria, or with MIA, which indicated that NLR plays an important role in the development and progression of DN.

It has also been demonstrated that chronic inflammation plays an important role in the development of DR with the help of various systemic and local (vitreous and aqueous fluids) inflammatory factors \[[@B82]\]. Neutrophils may contribute to the development and progression of microangiopathy and inflammation, when they adhere to the endothelial cell wall \[[@B86],[@B87]\]. A study by Woo et al. \[[@B88]\] showed that neutrophil count in circulation was higher in patients with DR, and was closely associated with DR grades, indicating the considerable role of neutrophil-mediated inflammation in the development and progression of DR. Furthermore, several recent literatures have proposed that NLR, as a novel inflammation marker, was found to be higher in patients with DR and linked with the severity of DR \[[@B13],[@B18],[@B61],[@B88],[@B89]\]. However, in a study by Ciray et al. \[[@B79]\], NLR was not found to be associated with the pathogenesis of DR. In our meta-analysis, it was observed that NLR might be involved in the presence of DR, but not linked with the DR grade, indicating that NLR might only play a role in the early stage of DR. However, only four studies with the low number of cases were in place for the meta-analysis of the association between NLR and the DR grade. Therefore, the role of NLR in the later stage of DR remains controversial and further studies are in need to figure out this issue.

Albuminuria can lead to some changes in the levels of numerous biomarkers in blood circulation, which could be applied to diagnosis and the risk evaluation of progression of kidney diseases \[[@B90],[@B91]\]. Several studies have shown that MPV and PDW values are higher in DM patients with DN when compared with those without DN. Similarly, our meta-analysis also demonstrated that DM patients with DN have increased level of MPV than those without DN. These results indicated that MPV and PDW values could be used for the diagnosis of DN. Furthermore, a few studies showed that the MPV values increased with DN stage proceeding, which suggested that MPV could be applied to determine the stage of DN and monitoring the progress of DN. Certainly, the exact causal association of MPV and PDW with DN need to be further explored, which will help physicians make full use of MPV and PDW in clinical practices.

It has been demonstrated that persistent presence of hyperglycemia, dyslipidemia, and insulin resistance could lead to endothelial and pericyte injury, which leaves DM patients in a 'prothrombotic condition' \[[@B92]\]. Furthermore, the morphologic and functional forms of platelets, which are related to enhanced platelet activity, were found to be increased in patients with DM \[[@B92]\]. Platelets with higher MPV value have more metabolic and enzymatic activities than the lower and produce more thromboxan-A~2~, b-thromboglobulin, and adhesion molecules releasing \[[@B19],[@B20]\], which implicated that MPV might be connected with elevated thrombotic potential. In consistence with numerous studies focussing on the correlation of MPV with DR, this meta-analysis also showed that increased MPV was associated with the presence of DR and its severity. In addition, PDW is a parameter reflecting the variability of platelet size, and its high value indicated increased production of larger reticulated platelet, indicating that PDW value, similar to MPV, is closely linked with thrombotic potential. Consistently, from the results of meta-analysis, we found that higher PDW was related to the presence of DR, but there were no differences in PDW between patients with NPDR and PDR. Considering that only five studies were available for the meta-analysis of the relationship of PDW to the severity of DR, the small sample size might partly account for the negative association of PDW with the severity of DR. Thus, further studies are needed to further explore the correlation between PDW and the severity of DR.

When interpreting the results of the present study, several limitations should be taken into consideration. First, although random-effect model was applied, significant heterogeneity amongst studies was still observed. It might be attributed to differences in some characteristics of the included studies including age, ethnicity, diseases' duration, and body mass index, in detecting instrument, in experimental designs and in quality of the included studies. Second, the number of included studies was insufficient for a persuasive meta-analysis of the association of NLR, MPV, and PDW with the DR grade. Third, the standard of the stage of DR/DN with T2DM patients was not uniform and may affect the results. Finally, this meta-analysis did not investigate the relationship of the NLR, MPV, and PDW to other factors that may influence the development of DR/DN, due to the lack of available data in the included studies.

In conclusion, this meta-analysis indicated that NLR MPV and PDW has a positive association with DN and DR. Furthermore, MPV is closely related to the severity of DR and DN. NLR, MPV, and PDW could be recommended as inexpensive diagnostic markers for DN and DR, and even antiplatelet agents might be effective to control the development of DN and DR. However, further high-quality clinical studies should be performed to investigate the relationship of NLR, MPV, and PDW to DN and DR.
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CI

:   confidence interval

DM

:   diabetes mellitus

DN

:   diabetic nephropathy

DR

:   diabetic retinopathy

MA

:   macroalbuminuria

MIA

:   microalbuminuria

MPV

:   mean platelet volume

NLR

:   neutrophil to lymphocyte ratio

NOS

:   Newcastle--Ottawa scale

NPDR

:   non-proliferative DR

PDW

:   platelet distribution width

PDR

:   proliferative DR

SD

:   sufficient data

SMD

:   standardized mean difference

T2DM

:   type Ⅱ DM
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